Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ORGANIZATION
ORGANIZATION
- Sales by 24 Member Companies Total 136.8 Billion Yen in 2013, with 12,361 Employees: JCROA
April 15, 2014
- Rattled Confidence, Dubious Eyes on Doctors “Unfortunate”: JMA Veep
April 11, 2014
- Number of CMRs Growing Rapidly in Anticipation of Major New Product Launches: JSCOA
April 11, 2014
- DSP Pres. Tada Likely to Head JPMA, Astellas’ Hatanaka Tipped for Chief Veep
April 10, 2014
- JPMA Suspends Veep Hasegawa’s Duties for 6 Months over CASE-J
April 4, 2014
- OPMA Appoints MTPC President Tsuchiya, Three Others as New Vice Chairmen
April 2, 2014
- JPMA to Ban Drug Makers from Giving Grants for Clinical Research on Own Products
March 28, 2014
- Funding Disclosures by 5 More FPMAJ Trade Groups to Get Underway in FY2014
March 27, 2014
- JPMA Reinstates Nihon Pharmaceutical Membership after 1-Year Suspension
March 25, 2014
- GHIT Fund Announces New Grants to Develop Treatments for Tropical Diseases, Novel Tuberculosis Vaccine
March 24, 2014
- JPMA Urges Takeda to Improve Promotion Regime over CASE-J
March 24, 2014
- Japanese Drug Makers Conduct MRCTs in More Countries, but Japan Ranks Just 24th as Trial Location: JPMA Survey
March 18, 2014
- JPWA Members to Display Delivery Prices without Tax from October
March 14, 2014
- 3,551 Contract Medical Sales Reps Work in Japan, Up 5.5%: Survey
March 13, 2014
- PhRMA Issues Principles on Investigator-Initiated Studies, Urges Drug Makers Not to Offer Labor
March 12, 2014
- PhRMA “Disappointed” by Rule Changes for Foreign Price Adjustments: New Japan Committee Chair
March 12, 2014
- FPMAJ Generic Guidelines Urge Makers to Create “Stable Supply” Officer Post
March 7, 2014
- JPMA Requests Takeda to Submit Report over CASE-J Issue
March 6, 2014
- Penalty for Lengthy Drug Price Haggling – Interview 3: JMA Exec Suzuki Calls for Cooperation to Defend Universal Healthcare
March 3, 2014
- Medwatcher Opposes Resumption of Active Recommendation for HPV Vaccines by Government
February 26, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…